T. Rowe Price Biotech ETF (TDNA) Price & Chart

Moderna (MRNA) expects 2026 revenue growth of 15% to 25%, compared with the original outlook of up to 10%, and is on track to achieve approximately 10 percentage points of

Biotech Analysts, along with multifocal motor neuropathy (MMN) Expert Dr. Jeffrey Allen, who discusses Dianthus’ (DNTH) and Argenx’s (ARGX) December MMN results on an Analyst/Industry conference call to be held

Option traders moderately bearish in Moderna (MRNA), with shares down $2.73 near $248.10. Options volume relatively light with 72k contracts traded and puts leading calls for a put/call ratio of

Moderna (MRNA) announced the publication of results from a large real-world study evaluating the comparative effectiveness of mNEXSPIKE and Comirnaty among U.S. Veterans aged 65 years and older during the

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

WSW, NY, November 11th, 2026, FinanceWire A reported offer for the established MC4R franchise and fresh funding for Lilly-backed Superluminal point to growing interest in the brain’s hunger pathway. Palatin

Moderna (($MRNA)) has held its Q3 earnings call. Read on for the main highlights of the call. Moderna’s earnings call carried a strongly positive tone, supported by 29% third-quarter revenue

Meeting to be held in National Habor, MD on November 15 hosted by Citizens. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Needham raised the firm’s price target on Liquidia (LQDA) to $66 from $58 and keeps a Buy rating on the shares. The company’s Q3 update “paints a more positive picture”